Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 7/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.55 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 7/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284018 | 0.81 | SCN2A (0.51) | SCN2ANPY5RPIN1MEN1NPC1 | |
| SCHEMBL15331826 | 0.81 | PDE10A (0.39) | SCN2ANPY5RPIN1MEN1NPC1 | |
| SCHEMBL15332782 | 0.81 | NISCH (0.42) | SCN2ANPY5RPIN1MEN1NPC1 | |
| SCHEMBL15331594 | 0.81 | TRPV1 (0.46) | SCN2ANPY5RPIN1MEN1NPC1 | |
| SCHEMBL15330385 | 0.80 | NPY5R (0.50) | NPY5RPIN1MEN1NPC1USP2 | |
| SCHEMBL15330826 | 0.80 | HPGDS (0.54) | SCN2APIN1MEN1NPC1USP2 | |
| SCHEMBL15333491 | 0.80 | HRH1 (0.56) | SCN2AMEN1NPC1USP2POLB | |
| SCHEMBL15331905 | 0.78 | COMT (0.57) | SCN2ANPY5RRAB9A | |
| SCHEMBL15332521 | 0.78 | SCN2A (0.55) | SCN2ANPC1MAPTRAB9ARECQL | |
| SCHEMBL8740568 | 0.78 | PIN1 (0.54) | SCN2ANPY5RPIN1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2831071-B1 | IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-11-14 | — | — | EP | disclosed |
| US-9051299-B2 | Imidazolyl methyl piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051299-B2 | Imidazolyl methyl piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051299-B2 | Imidazolyl methyl piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150051248-A1 | IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-02-19 | — | — | US | disclosed |
| US-20150051248-A1 | IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-02-19 | — | — | US | disclosed |
| US-20150051248-A1 | IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-02-19 | — | — | US | disclosed |
| EP-1699779-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061484-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-RE30511-E | ENZYME INHIBITOR, HERBICIDE, CYCLIZATION | AMERICAN CYANAMID COMPANY (US) | 1981-02-10 | — | — | US | disclosed |
| US-4168964-A | HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1979-09-25 | — | — | US | disclosed |
| US-4107307-A | ENZYME INHIBITORS, HERBICIDES, RING CLOSURE | AMERICAN CYANAMID COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | SCN2A 357/4885NPY5R 3783/4885PIN1 3767/4885 |
| US-20150051248-A1 | IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1I, CACNA1G, CACNA1H | SCN2A 184/4885NPY5R 2032/4885PIN1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.